Last update 01 Nov 2024

endonuclease Cas9 x Cep290

Basic Info

Related Targets
endonuclease Cas9Cep290

Related

1
Drugs associated with endonuclease Cas9 x Cep290
Brinretigene vesgedparvovec
Target
Cep290 x endonuclease Cas9
Mechanism
Cep290 modulators [+2]
Active Org.
Editas Medicine, Inc.Editas Medicine, Inc. [+1]
Originator Org.
Editas Medicine, Inc.Editas Medicine, Inc.
Active Indication
Leber Congenital Amaurosis [+5]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with endonuclease Cas9 x Cep290
NCT03872479 / Active, not recruitingPhase 1/2
Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26")
100 Clinical Results associated with endonuclease Cas9 x Cep290
Login to view more data
100 Translational Medicine associated with endonuclease Cas9 x Cep290
Login to view more data
0 Patents (Medical) associated with endonuclease Cas9 x Cep290
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free